Skip to main
AUTL

Autolus Therapeutics (AUTL) Stock Forecast & Price Target

Autolus Therapeutics (AUTL) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Autolus Therapeutics is developing an advanced portfolio of programmed T-cell therapies, utilizing innovative technologies to enhance the properties of T-cells for personalized and effective treatment of cancer. The company's diverse pipeline and strong clinical results position them well for future growth and success in the competitive biopharmaceutical market. Additionally, with increasing recognition and support for CAR-T therapy, Autolus is well-positioned to capitalize on the potential of this innovative treatment approach, making it a promising investment opportunity.

Bears say

Autolus Therapeutics is facing stiff competition in the CAR-T space from established players like Novartis and Gilead, as well as upcoming technologies such as allogeneic CAR-T therapies. Their lead product, Aucatzyl, has received FDA approval for r/r B-cell acute lymphoblastic leukemia (B-ALL) but has limited market potential due to its rare incidence. Their potential move into the frontline consolidation setting and expansion into other indications is still years away, with potential changes in clinical guidelines and practice patterns still uncertain. Additionally, the company's financial outlook for the near term is softer than expected, with projected sales and cash on hand not aligning with estimates by analysts. This, combined with potential challenges in patent protection and regulatory approval, leads to a negative outlook on Autolus Therapeutics' stock.

Autolus Therapeutics (AUTL) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Autolus Therapeutics (AUTL) Forecast

Analysts have given Autolus Therapeutics (AUTL) a Buy based on their latest research and market trends.

According to 4 analysts, Autolus Therapeutics (AUTL) has a Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Autolus Therapeutics (AUTL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.